|
US2292551A
(en)
*
|
1940-01-26 |
1942-08-11 |
Du Pont |
Naphthostyril-5-carboxylic acid
|
|
IT1123076B
(it)
*
|
1976-11-17 |
1986-04-30 |
Acna |
Procedimento di preparazione diretta di 6-amino-benz-(cd)-indol-2-(1h)-oni-n-mono oppure n,n-disostituiti
|
|
DE2921690A1
(de)
*
|
1979-05-29 |
1980-12-11 |
Basf Ag |
Naphtholactamderivate
|
|
IL99500A0
(en)
*
|
1990-09-17 |
1992-08-18 |
Agouron Pharma |
Naphthalene compounds,processes for the preparation thereof and pharmaceutical compositions containing the same
|
|
WO1992010591A1
(en)
|
1990-12-14 |
1992-06-25 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
JP3286056B2
(ja)
*
|
1993-01-18 |
2002-05-27 |
武田薬品工業株式会社 |
三環式縮合複素環誘導体、その製造法および用途
|
|
US5565215A
(en)
|
1993-07-23 |
1996-10-15 |
Massachusettes Institute Of Technology |
Biodegradable injectable particles for imaging
|
|
GB9322014D0
(en)
|
1993-10-26 |
1993-12-15 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
|
SE9401108D0
(sv)
|
1994-03-31 |
1994-03-31 |
Leiras Oy |
Ophthalmic composition I
|
|
SE9401109D0
(sv)
|
1994-03-31 |
1994-03-31 |
Leiras Oy |
Opthalmic composition II
|
|
GB9412273D0
(en)
|
1994-06-18 |
1994-08-10 |
Univ Nottingham |
Administration means
|
|
US6007845A
(en)
|
1994-07-22 |
1999-12-28 |
Massachusetts Institute Of Technology |
Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
|
|
GB9501841D0
(en)
|
1995-01-31 |
1995-03-22 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
|
US6413539B1
(en)
|
1996-10-31 |
2002-07-02 |
Poly-Med, Inc. |
Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
|
|
GB9515182D0
(en)
|
1995-07-24 |
1995-09-20 |
Co Ordinated Drug Dev |
Improvements in and relating to powders for use in dry powder inhalers
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
TR200101502T2
(tr)
|
1998-03-16 |
2002-06-21 |
Celgene Corporation |
2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
|
|
US6045501A
(en)
|
1998-08-28 |
2000-04-04 |
Celgene Corporation |
Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
|
|
GB9827145D0
(en)
|
1998-12-09 |
1999-02-03 |
Co Ordinated Drug Dev |
Improvements in or relating to powders
|
|
US6287588B1
(en)
|
1999-04-29 |
2001-09-11 |
Macromed, Inc. |
Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
|
|
WO2001074400A1
(en)
|
2000-04-03 |
2001-10-11 |
Santen Pharmaceutical Co., Ltd. |
Transporters and drug delivery system by using the same
|
|
GB0009468D0
(en)
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formulations for use in inhaler devices
|
|
US6589549B2
(en)
|
2000-04-27 |
2003-07-08 |
Macromed, Incorporated |
Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
|
|
JP5698423B2
(ja)
|
2000-06-27 |
2015-04-08 |
ベクトゥラ・リミテッド |
医薬組成物で使用するための粒子の製造法
|
|
GB2364919A
(en)
|
2000-07-21 |
2002-02-13 |
Cambridge Consultants |
Inhalers
|
|
US6315720B1
(en)
|
2000-10-23 |
2001-11-13 |
Celgene Corporation |
Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
|
|
CN1507357A
(zh)
|
2000-10-31 |
2004-06-23 |
PRҩƷ����˾ |
提高生物活性分子传递的方法和组合物
|
|
ATE338124T1
(de)
|
2000-11-07 |
2006-09-15 |
Hope City |
Cd19-spezifische umgezielte immunzellen
|
|
DE60140268D1
(de)
|
2000-11-30 |
2009-12-03 |
Vectura Ltd |
Partikel zur verwendung in einer pharmazeutischen zusammensetzung
|
|
US6504034B2
(en)
*
|
2001-01-23 |
2003-01-07 |
Hoffmann-La Roche Inc. |
Naphthostyrils
|
|
GB0122318D0
(en)
|
2001-09-14 |
2001-11-07 |
Novartis Ag |
Organic compounds
|
|
WO2003057171A2
(en)
|
2002-01-03 |
2003-07-17 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US7230012B2
(en)
|
2002-11-14 |
2007-06-12 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
|
JP2007505831A
(ja)
|
2003-09-15 |
2007-03-15 |
ベクトゥラ・リミテッド |
肺吸入による、早漏を治療するための医薬品組成物
|
|
KR20060085246A
(ko)
|
2003-09-18 |
2006-07-26 |
마커사이트, 인코포레이티드 |
경공막 전달
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
GB0407627D0
(en)
|
2004-04-02 |
2004-05-05 |
Vectura Ltd |
Corkscrew pump
|
|
ES2246694B1
(es)
|
2004-04-29 |
2007-05-01 |
Instituto Cientifico Y Tecnologico De Navarra, S.A. |
Nanoparticulas pegiladas.
|
|
WO2006026746A2
(en)
|
2004-08-31 |
2006-03-09 |
The Government Of United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods to separate and expand antigen-specific t cells
|
|
US8663639B2
(en)
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
|
DK1848431T3
(en)
|
2005-02-09 |
2016-04-18 |
Santen Pharmaceutical Co Ltd |
LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
|
|
US20070071756A1
(en)
|
2005-09-26 |
2007-03-29 |
Peyman Gholam A |
Delivery of an agent to ameliorate inflammation
|
|
JP5819579B2
(ja)
|
2006-01-13 |
2015-11-24 |
サーモディクス，インコーポレイティド |
薬物送達のためのマトリックスを含む微粒子
|
|
ES2563288T3
(es)
|
2006-03-23 |
2016-03-14 |
Santen Pharmaceutical Co., Ltd |
Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
|
|
US20080166411A1
(en)
|
2006-04-10 |
2008-07-10 |
Pfizer Inc |
Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
|
|
CL2007002218A1
(es)
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
|
CL2007002513A1
(es)
|
2006-08-30 |
2008-04-04 |
Celgene Corp Soc Organizada Ba |
Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
CL2007002670A1
(es)
|
2006-09-15 |
2008-05-16 |
Celgene Corp Soc Organizada Ba |
Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis.
|
|
ME02420B
(me)
|
2006-09-26 |
2016-09-20 |
Celgene Corp |
5-supstituirani derivati kinazolinona kao sredstva protiv raka
|
|
MX2009010082A
(es)
|
2007-03-20 |
2009-10-19 |
Celgene Corp |
Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma.
|
|
CA2704710C
(en)
|
2007-09-26 |
2016-02-02 |
Celgene Corporation |
6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same
|
|
US9943401B2
(en)
|
2008-04-04 |
2018-04-17 |
Eugene de Juan, Jr. |
Therapeutic device for pain management and vision
|
|
US20090298882A1
(en)
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
|
AU2009273130B2
(en)
|
2008-07-25 |
2014-10-16 |
Glaxo Group Limited |
Novel compositions and methods
|
|
PT2358697E
(pt)
|
2008-10-29 |
2016-02-03 |
Celgene Corp |
Compostos de isoindolina para utilização no tratamento do cancro
|
|
US8623395B2
(en)
|
2010-01-29 |
2014-01-07 |
Forsight Vision4, Inc. |
Implantable therapeutic device
|
|
AU2010208046B2
(en)
|
2009-01-29 |
2014-10-02 |
Forsight Vision4, Inc. |
Posterior segment drug delivery
|
|
WO2010091187A2
(en)
|
2009-02-04 |
2010-08-12 |
The Brigham And Women's Hospital, Inc. |
Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
|
|
WO2010093662A2
(en)
|
2009-02-10 |
2010-08-19 |
Psivida Us, Inc. |
Ocular trocar assembly
|
|
US10952965B2
(en)
|
2009-05-15 |
2021-03-23 |
Baxter International Inc. |
Compositions and methods for drug delivery
|
|
BRPI1007855B1
(pt)
|
2009-05-19 |
2020-03-10 |
Celgene Corporation |
Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona
|
|
EP2437684B1
(en)
|
2009-06-03 |
2022-06-15 |
ForSight Vision5, Inc. |
Anterior segment drug delivery
|
|
CN102625832A
(zh)
|
2009-08-24 |
2012-08-01 |
贝勒医学院 |
产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
|
|
US9556426B2
(en)
|
2009-09-16 |
2017-01-31 |
Celgene Avilomics Research, Inc. |
Protein kinase conjugates and inhibitors
|
|
EP2490620A4
(en)
|
2009-10-23 |
2017-03-22 |
Forsight Labs, Llc |
Conformable therapeutic shield for vision and pain
|
|
US20130066283A1
(en)
|
2009-10-23 |
2013-03-14 |
Nexisvision, Inc. |
Corneal Denervation for Treatment of Ocular Pain
|
|
WO2013022801A1
(en)
|
2011-08-05 |
2013-02-14 |
Forsight Vision4, Inc. |
Small molecule delivery with implantable therapeutic device
|
|
RS56042B1
(sr)
|
2010-06-10 |
2017-09-29 |
Seragon Pharmaceuticals Inc |
Modulatori estrogenih receptora i njihove upotrebe
|
|
CN103209664A
(zh)
|
2010-08-05 |
2013-07-17 |
弗赛特影像4股份有限公司 |
可植入的治疗装置
|
|
EP3861969A1
(en)
|
2010-08-05 |
2021-08-11 |
ForSight Vision4, Inc. |
Injector apparatus for drug delivery
|
|
AU2011285548B2
(en)
|
2010-08-05 |
2014-02-06 |
Forsight Vision4, Inc. |
Combined drug delivery methods and apparatus
|
|
CA2807508A1
(en)
|
2010-08-05 |
2012-02-09 |
Forsight Vision4, Inc. |
Subconjunctival implant for posterior segment drug delivery
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
US20140033800A1
(en)
|
2010-11-11 |
2014-02-06 |
Forsight Vision4, Inc. |
Methods and apparatus to determine diffusion properties of porous structures for drug delivery
|
|
TW201304822A
(zh)
|
2010-11-15 |
2013-02-01 |
Vectura Ltd |
組成物及用途
|
|
WO2012068549A2
(en)
|
2010-11-19 |
2012-05-24 |
Forsight Vision4, Inc. |
Therapeutic agent formulations for implanted devices
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012175481A1
(en)
|
2011-06-20 |
2012-12-27 |
Institut Curie |
Compositions and methods for treating leukemia
|
|
JP5989780B2
(ja)
|
2011-09-14 |
2016-09-07 |
フォーサイト・ビジョン５・インコーポレイテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ５，Ｉｎｃ． |
眼挿入装置および方法
|
|
PT2755600T
(pt)
|
2011-09-16 |
2021-04-19 |
Forsight Vision4 Inc |
Aparelhos de troca de fluidos
|
|
WO2013044225A1
(en)
|
2011-09-22 |
2013-03-28 |
The Trustees Of The University Of Pennsylvania |
A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
KR101749195B1
(ko)
|
2011-12-12 |
2017-06-20 |
셀 메디카 리미티드 |
T 세포들을 증식시키는 방법
|
|
EP2724741B1
(en)
|
2012-10-26 |
2017-06-14 |
Vectura GmbH |
Inhalation device for use in aerosol therapy
|
|
PT2797652T
(pt)
|
2011-12-27 |
2019-02-19 |
Vectura Gmbh |
Dispositivo para inalação com sistema de feedback
|
|
KR102668696B1
(ko)
|
2012-01-12 |
2024-05-29 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
WO2013116061A1
(en)
|
2012-02-03 |
2013-08-08 |
Forsight Vision4, Inc. |
Insertion and removal methods and apparatus for therapeutic devices
|
|
ES2748652T3
(es)
|
2012-02-09 |
2020-03-17 |
Baylor College Medicine |
Mezclas pep para generar CTL multivíricos con amplia especificidad
|
|
CA2861491C
(en)
|
2012-02-13 |
2020-08-25 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
EP2846859B1
(en)
|
2012-03-09 |
2017-01-04 |
Vectura GmbH |
Mixing channel for an inhalation device and inhalation device
|
|
US20140107025A1
(en)
|
2012-04-16 |
2014-04-17 |
Jade Therapeutics, Llc |
Ocular drug delivery system
|
|
JP2015524255A
(ja)
|
2012-07-13 |
2015-08-24 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
|
|
JP5998717B2
(ja)
|
2012-07-31 |
2016-09-28 |
ブラザー工業株式会社 |
液体吐出装置
|
|
EP2895146A1
(en)
|
2012-09-17 |
2015-07-22 |
BIND Therapeutics, Inc. |
Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
|
|
KR20150090038A
(ko)
|
2012-09-20 |
2015-08-05 |
아키나, 인크. |
충전재를 함유한 생분해성 미세캡슐
|
|
RU2652063C2
(ru)
|
2012-10-26 |
2018-04-24 |
Форсайт Вижн5, Инк. |
Офтальмологическая система для замедленного высвобождения лекарственного средства в глазу
|
|
AU2013337717B2
(en)
|
2012-11-01 |
2018-10-25 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using PI3 kinase isoform modulators
|
|
WO2014152959A1
(en)
|
2013-03-14 |
2014-09-25 |
Forsight Vision4, Inc. |
Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
|
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
CN105246438B
(zh)
|
2013-03-28 |
2018-01-26 |
弗赛特影像4股份有限公司 |
用于输送治疗物质的眼科植入物
|
|
EP3057514A4
(en)
|
2013-10-15 |
2017-08-02 |
Forsight Vision5, Inc. |
Formulations and methods for increasing or reducing mucus
|
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
|
WO2015085234A1
(en)
|
2013-12-06 |
2015-06-11 |
Forsight Vision4, Inc. |
Implantable therapeutic devices
|
|
WO2015085172A2
(en)
|
2013-12-06 |
2015-06-11 |
Celgene Corporation |
Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
|
|
US9802920B2
(en)
|
2013-12-13 |
2017-10-31 |
Hoffman-La Roche Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
RU2738833C9
(ru)
|
2014-04-14 |
2022-02-28 |
Арвинас, Оперэйшнз, Инк. |
Имидные модуляторы протеолиза и способы их применения
|
|
MY191537A
(en)
|
2014-12-05 |
2022-06-30 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
MA41346A
(fr)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
Eléments régulateurs post-transcriptionnels d'hépatite modifiée
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
CN111662226B
(zh)
|
2015-01-28 |
2022-03-18 |
中国科学院广州生物医药与健康研究院 |
一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物
|
|
EP3270917A4
(en)
|
2015-03-18 |
2018-08-08 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
US20180072990A1
(en)
|
2015-03-20 |
2018-03-15 |
Children's National Medical Center |
Generating virus or other antigen-specific t cells from a naïve t cell population
|
|
KR102349677B1
(ko)
|
2015-05-28 |
2022-01-12 |
카이트 파마 인코포레이티드 |
T 세포 요법을 위해 환자를 컨디셔닝하는 방법
|
|
CA2988414C
(en)
|
2015-06-04 |
2023-09-26 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
EP3306873B1
(en)
|
2015-06-30 |
2019-09-11 |
Huawei Technologies Co., Ltd. |
Routing method, and relevant device and system
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
KR101818756B1
(ko)
|
2015-12-30 |
2018-02-21 |
유한회사 한국 타코닉 |
방수방식 조성물 및 이를 이용한 방수방식 필름
|
|
WO2017117474A1
(en)
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional compounds for her3 degradation and methods of use
|
|
US10599788B2
(en)
|
2015-12-30 |
2020-03-24 |
International Business Machines Corporation |
Predicting target characteristic data
|
|
WO2017117473A1
(en)
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molescules for her3 degradation and methods of use
|
|
KR102331013B1
(ko)
|
2016-01-14 |
2021-11-26 |
강푸 바이오파마슈티칼즈 리미티드 |
퀴나졸리논 유도체, 이의 제조방법, 약학 조성물 및 적용
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
AU2017254713C1
(en)
|
2016-04-22 |
2021-04-29 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for degradation of EGFR and methods of use
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017197056A1
(en)
*
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
|
WO2017203356A1
(en)
|
2016-05-25 |
2017-11-30 |
The Council Of The Queensland Institute Of Medical Research |
Methods of immunotherapy
|
|
MX2019000180A
(es)
|
2016-06-28 |
2019-11-05 |
Geneius Biotechnology Inc |
Composiciones de células t para la inmunoterapia.
|
|
US20180072711A1
(en)
|
2016-09-15 |
2018-03-15 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
KR102368555B1
(ko)
|
2016-12-16 |
2022-02-28 |
강푸 바이오파마슈티칼즈 리미티드 |
조성물, 이의 적용 및 치료 방법
|
|
US10040804B2
(en)
|
2016-12-21 |
2018-08-07 |
Biotheryx, Inc. |
Compounds targeting proteins, compositions, methods, and uses thereof
|
|
KR20250117470A
(ko)
|
2016-12-23 |
2025-08-04 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
|
JP2020505327A
(ja)
|
2016-12-23 |
2020-02-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
BR112019015312A2
(pt)
|
2017-01-26 |
2020-03-10 |
Arvinas Operations, Inc. |
Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
|
|
JP7227912B2
(ja)
|
2017-02-08 |
2023-02-24 |
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド |
キメラ抗原受容体の調節
|
|
AU2018219292B2
(en)
|
2017-02-08 |
2024-09-26 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation with heterobifunctional compounds
|
|
CA3053805C
(en)
|
2017-02-13 |
2020-06-30 |
Kangpu Biopharmaceuticals, Ltd. |
Combination treating prostate cancer, pharmaceutical composition and treatment method
|
|
DK3590924T3
(da)
|
2017-02-28 |
2022-01-03 |
Kangpu Biopharmaceuticals Inc |
Hidtil ukendt isoindolinderivat og farmaceutisk sammensætning og anvendelse deraf
|
|
WO2018220149A1
(en)
|
2017-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Compounds
|
|
WO2018226542A1
(en)
|
2017-06-09 |
2018-12-13 |
Arvinas, Inc. |
Modulators of proteolysis and associated methods of use
|
|
US20200190136A1
(en)
|
2017-06-09 |
2020-06-18 |
Dana-Farber Cancer Institute, Inc. |
Methods for generating small molecule degraders and dimerizers
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
EP4467143B1
(en)
|
2017-07-10 |
2026-03-11 |
Celgene Corporation |
Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile
|
|
ES2965049T3
(es)
|
2017-07-12 |
2024-04-10 |
Dana Farber Cancer Inst Inc |
Compuestos para la degradación de la proteína tau
|
|
EP3658548A1
(en)
|
2017-07-28 |
2020-06-03 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
TWI793151B
(zh)
*
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
WO2019079701A1
(en)
|
2017-10-20 |
2019-04-25 |
Dana-Farber Cancer Institute, Inc. |
HETEROBIFUNCTIONAL COMPOUNDS HAVING IMPROVED SPECIFICITY FOR BRD4 BROMODOMAINE
|
|
US20200348285A1
(en)
|
2017-11-09 |
2020-11-05 |
Dana-Farber Cancer Institute, Inc. |
Methods to prevent teratogenicity of imid like molecules and imid based degraders/protacs
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
CN111372585A
(zh)
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
EP3724216A1
(en)
|
2017-12-15 |
2020-10-21 |
Dana Farber Cancer Institute, Inc. |
Stabilized peptide-mediated targeted protein degradation
|
|
JP2021506848A
(ja)
|
2017-12-18 |
2021-02-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｅ３ユビキチンリガーゼ部分を持つｅｇｆｒを有する二官能性阻害剤
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019148055A1
(en)
|
2018-01-26 |
2019-08-01 |
Yale University |
Imide-based modulators of proteolysis and methods of use
|
|
TW201945357A
(zh)
|
2018-02-05 |
2019-12-01 |
瑞士商赫孚孟拉羅股份公司 |
化合物
|
|
CA3090417A1
(en)
|
2018-02-23 |
2019-08-29 |
Dana-Farber Cancer Institute, Inc. |
Small molecules for inducing selective protein degradation and uses thereof
|
|
EP3773576A4
(en)
|
2018-03-26 |
2021-12-29 |
C4 Therapeutics, Inc. |
Cereblon binders for the degradation of ikaros
|
|
US20190300521A1
(en)
|
2018-04-01 |
2019-10-03 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
WO2019195609A2
(en)
|
2018-04-04 |
2019-10-10 |
Arvinas Operations, Inc. |
Modulators of proteolysis and associated methods of use
|
|
IL302595A
(en)
|
2018-04-13 |
2023-07-01 |
Arvinas Operations Inc |
Servalon ligands and bifunctional compounds containing them
|
|
EP3781156A4
(en)
|
2018-04-16 |
2022-05-18 |
C4 Therapeutics, Inc. |
SPIROCYCLIC COMPOUNDS
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
CA3101338A1
(en)
|
2018-06-13 |
2019-12-19 |
Biotheryx, Inc. |
Aminoamide compounds
|
|
US12030892B2
(en)
|
2018-06-29 |
2024-07-09 |
Dana-Farber Cancer Institute, Inc. |
CRBN modulators
|
|
EP3814330A4
(en)
|
2018-06-29 |
2022-07-20 |
Dana-Farber Cancer Institute, Inc. |
Immunomodulatory compounds
|
|
US12060366B2
(en)
|
2018-06-29 |
2024-08-13 |
Dana-Farber Cancer Institute, Inc. |
Bispecific degraders
|
|
WO2020010210A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
CA3102996A1
(en)
|
2018-07-20 |
2020-01-23 |
Dana-Farber Cancer Institute, Inc. |
Degraders that target proteins via keap1
|
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
|
JP7297053B2
(ja)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
|
|
WO2020051235A1
(en)
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
IL281188B2
(en)
|
2018-09-07 |
2025-08-01 |
Arvinas Operations Inc |
Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
US12318452B2
(en)
|
2018-09-27 |
2025-06-03 |
Dana-Farber Cancer Institute, Inc. |
Degraders of WEE1 kinase
|
|
EP3856190A4
(en)
|
2018-09-27 |
2022-09-21 |
Dana Farber Cancer Institute, Inc. |
DEGRADATION OF FAK OR FAK AND ALK BY CONJUGATION OF FAK AND ALK INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
|
|
WO2020069125A1
(en)
|
2018-09-28 |
2020-04-02 |
Dana-Farber Cancer Institute, Inc. |
Degraders of hepatitis c virus ns3/4a protein
|
|
AU2020336381A1
(en)
|
2019-08-27 |
2022-03-03 |
The Regents Of The University Of Michigan |
Cereblon E3 ligase inhibitors
|
|
EP4077319A1
(en)
|
2019-12-20 |
2022-10-26 |
Calico Life Sciences LLC |
Protein tyrosine phosphatase degraders and methods of use thereof
|
|
TWI887465B
(zh)
*
|
2020-08-07 |
2025-06-21 |
美商Ｃ４醫藥公司 |
用於伊卡洛斯(ikaros)或愛露斯(aiolos)介導之病症之有利療法
|
|
CA3228839A1
(en)
*
|
2021-08-27 |
2023-03-02 |
Liqiang Fu |
Isoindolinone compound and use thereof
|
|
JP2025505687A
(ja)
*
|
2022-02-09 |
2025-02-28 |
シーフォー セラピューティクス， インコーポレイテッド |
Ｃｆｔ７４５５のモルフィック形態及びその製造方法
|